he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源电话号码
上一页:哪些抗菌药品可诱发癫痫?
- 2022-05-022013年国际抗癫痫理事会抗癫痫药使用指南
- 2022-04-28卒中后哮喘首选用药有哪些?解答卒中后哮喘的4大问题
- 2022-04-07综述:癫痫持续状态诊治最新进展
- 月经性癫痫患者妊娠期癫痫控制更好
- 罕见病例:自发性颞极性扩张伴癫痫发作
- J Allergy Clin Immunol:奥马珠单抗治疗鼻息肉病的安全性:2次随机3次试验
- 综述:癫痫持续状态诊治最新进展
- 药学版元宵灯谜 看你能猜对几个问题
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫治愈费用
- 帕金森病非运动症状的识别和治疗
- 癫痫猝死:凶手是谁?
- 三庚酸酯可治疗1型转运体缺陷综合征
- 癫痫的治疗费用是多少?
- 抗癫痫药物预防新发癫痫:任重而道远
- Medpage Today:不同类型的抗癫痫药物更有利
- 冒犯多囊卵巢综合征,身体会有这些变化,不容忽视
- 癫痫治疗障碍仍难以克服
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫的治疗方法 中医拔罐治疗癫痫的小方法(2)
- 什么是治疗癫痫 癫痫有这些偏方?
- JAMA Surg:破裂是影响局限性胃肠道间质瘤患者术后生存期的重要因素
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 非淋菌性炎的症状是什么
- 预测癫痫患者再入院风险
- 结核性淋巴炎吃什么好
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫诊断的依据是什么?
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 沈阳癫痫病医院病人费用是多少
- 【用药情报站】五花八门的药物禁忌证,临床应用该不行谁的?
- 脑炎中风 治疗脑炎中风的方法有哪些
- 【点赞广东好医生】广医二院廖卫平:甘坐科研“冷板凳”,勇攀核心技术新高峰
- Circ ep:检测器机自动诊断可能漏诊部分QTc延长者
- 世界性癫痫日|遇到癫痫发作,如何紧急应对?
- 降低缺血性薨中后癫痫风险,就靠这种神药
- 第九届 CAAE 国际癫痫论坛圆满举行,中国抗癫痫事业掀开新篇章
- 癫痫病的治疗开销是多少
- 带鱼点心 带鱼不一样的吃法
- 挥食疗法 什么是挥食疗法
- 区域和全身对提高额颞叶开颅手术患者术后早期疼痛和类药物使用作用的比较
- 世界发作日 | 科学防治 规范诊疗 告别发作